ArticleIJID regions2025
Investigating persistent measles dynamics associated with population immunity in Chad: a national secondary data model analysis from 2011 to 2025.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objectives: To model the population measles immunity gaps in a birth cohort of children aged 0-14 years in Chad from 2011 to 2025. Methods: This study used the Centers for Disease Control and Prevention-established population modeling analysis measles immunity profile approach, including data published by World Health Organization, United Nations Children's Fund, and United Nations Population. Excel and R Software were used to build a stacked bar chart of population immunity using immunity by measles-containing vaccine (MCV) dose 1 (MCV1) (%), by MCV dose 2 (MCV2) (%), by supplemental immunization activities (%), by maternal antibodies (%), and the rate of unprotected individuals against measles. Results: The population immunity gaps ranged from 5% to 6% in the cohort of children born in 2011-2013. We estimated the immunity gaps to be 13% in 2014-2015. Our results revealed an increase in population immunity gaps of 21% in 2016 and 2017 and 20% computed in 2018. From 2019 to 2022, the immunity gaps are ranged from 6% to 8%, correlating with a decrease of three to four times less than 2016-2018. A significant increase in immunity was observed in 2023, 2024, and 2025, with 46%, 53%, and 36%, respectively. The overall cohort showed a significative cumulative number of cases of measles susceptibility correlated with population immunity gaps. The findings also revealed insufficient MCV1 coverage, a late introduction of MCV2, poor MCV2 coverage, and a high MCV1/MCV2 abandonment rate over time. Conclusions: The risk of recurrent measles outbreaks remains high because of high population immunity profile gaps, increasing the population susceptible. To address immunity gaps, it is necessary to increase coverage by routine vaccination and high-quality supplemental immunization activities in Chad.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.